Completed

MK-1084 Effects on Rosuvastatin and Metformin in Healthy Individuals

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Rosuvastatin

+ Metformin

+ MK-1084

Drug
Who is being recruted

From 19 to 60 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Basic Science Study

Phase 1
Interventional
Study Start: November 2025
See protocol details

Summary

Principal SponsorMerck Sharp & Dohme LLC
Last updated: January 15, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 19, 2025

Actual date on which the first participant was enrolled.

This study aims to understand how a new drug, MK-1084, affects the levels of two commonly used medications, rosuvastatin and metformin, in the bodies of healthy individuals. Rosuvastatin is typically used to lower cholesterol, and metformin is often prescribed for managing blood sugar levels in people with type 2 diabetes. By observing how MK-1084 influences these drugs, researchers hope to determine if it changes the way these medications are processed in the body, which could be important for ensuring safe and effective use of these drugs in combination in future treatments. Participants in the study will receive single doses of rosuvastatin and metformin, both with and without MK-1084, in different periods of the study. This approach helps researchers compare the amount of rosuvastatin and metformin in the body over time under both conditions. The study aims to measure how MK-1084 influences the absorption, breakdown, and elimination of these medications. There are no specific risks or benefits mentioned for participants, but close monitoring ensures participant safety while gathering valuable data on drug interactions.

Official TitleAn Open-Label, 2-Period, Crossover Study to Evaluate the Effects of a Single Dose of MK-1084 on the Single-Dose Pharmacokinetics of Rosuvastatin and Metformin in Healthy Participants 
NCT07222098
Principal SponsorMerck Sharp & Dohme LLC
Last updated: January 15, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

16 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Basic Science Study

Basic science studies help researchers understand how the body works or how a disease develops. They don't test treatments, but they build the foundation for future therapies.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 19 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

1 inclusion criteria required to participate
Has body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2
2 exclusion criteria prevent from participating
Has history of cancer (malignancy)
Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Participants will receive rosuvastatin plus metformin

Group II

Experimental
Participants will receive rosuvastatin plus metformin plus MK-1084

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Celerion ( Site 0001)

Lincoln, United StatesSee the location
CompletedOne Study Center